CFCamilla Bärthel Flaaten

Camilla Bärthel Flaaten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camilla Bärthel Flaaten has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Art of Not Knowing: Accommodating Structured Missingness in Biomedical Research

    by Barbora Rehak Buckova, Charlotte Fraza, Cecilie Koldbaek, Camilla Barthel Flaaten, Linn Sofie Saether, Giulia Cattarinussi, Karen Marie Sando Ambrosen, Ole Andreas Andreassen, Lars T. Westlye, Christian Beckmann, et al.

    Missing data remain a ubiquitous and critical challenge in large-scale clinical studies. Despite advances in imputation, most existing methods fail to address structured missingness, where data are missing according a deterministic pattern and which arise due to systematic patterns introduced by experimental design, site protocols, or cohort differences. These patterns violate key assumptions of most imputation algorithms, yet their impact is rarely evaluated. We demonstrate that structured missingness is a fundamental challenge to drawing valid inferences from standard imputation techniques. First, we present a comprehensive framework for understanding and accommodating the effects of structured missingness. Next, we show through simulations and real-world psychometric data with structured missingness, that widely used algorithms optimised for numerical precision (e.g., Extra Trees, AutoComplete) underperform due to site effects, while donor-based methods (e.g., MICE, hierarchical MICE) better preserve multivariate structure. We propose a novel hierarchical approach that provides optimal performance in simulated and experimental data. Finally, we show that commonly used accuracy metrics, such as mean squared error can obscure these failures, and are therefore inadequate for the evaluation of structured missingness. In contrast, other divergence-based metrics offer a more sensitive and interpretable alternative. We apply this approach to harmonising psychometric data across cohorts, which provides excellent item-level alignment across different instruments. Our study highlights the need for a paradigm shift in handling missing data within biomedical research, moving beyond conventional imputation frameworks to develop tools that can account for structured missingness. This shift is essential for ensuring reliable inference in multi-site clinical studies, precision medicine, and large-scale population analyses.


  • Open Access

    Longitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls

    by Linn Sofie Sæther, Thor Ueland, Beathe Haatveit, Anja Vaskinn, Camilla Bärthel Flaaten, Christine Mohn, Monica B. E.G. Ormerod, Pål Aukrust, Ingrid Melle, Nils Eiel Steen, et al.

    Background: While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship.Methods: Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n = 221), and healthy controls (HC, n = 220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups.Results: There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course.Conclusions: Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.


  • Open Access

    Longitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls

    by Linn Sofie Sæther, Thor Ueland, Beathe Haatveit, Anja Vaskinn, Camilla Bärthel Flaaten, Christine Mohn, Monica B. E.G. Ormerod, Pål Aukrust, Ingrid Melle, Nils Eiel Steen, et al.

    Background While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship. Methods Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n=221), and healthy controls (HC, n=220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups. Results There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course. Conclusions Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.

  • Open Access

    Long‐term course of cognitive functioning in bipolar disorder: A ten‐year follow‐up study

    by Camilla Bärthel Flaaten, Ingrid Melle, Thomas Bjella, Magnus Johan Engen, Gina Åsbø, Kristin Fjelnseth Wold, Line Widing, Erlend Gardsjord, Merete Glenne Øie, Siv Hege Lyngstad, et al.

    Introduction: Cognitive impairments are common in bipolar disorder (BD), but the long‐term course remains understudied. Longitudinal data on cognitive functioning from the start of the first treatment could help clarify pathophysiological processes that shape the illness outcome. We here aim to investigate the 10‐year cognitive course in BD compared to healthy controls (HC) and the effects of clinical symptoms on cognitive trajectories.Methods: Fifty‐six BD participants recruited within their first year of treatment and 108 HC completed clinical and cognitive assessments at baseline and 10‐year follow‐up. We derived eight cognitive domain scores and a cognitive composite score, which were further investigated using linear mixed model analyses. Correlation analyses were used to assess associations between the composite score and depressive, manic and psychotic symptoms.Results: BD participants performed poorer than HCs in all domains except mental speed and verbal fluency. Verbal learning and memory, verbal fluency and the composite score improved over time in both BD participants and HC, while short‐term memory, mental speed, psychomotor speed and working memory were stable. We found no significant correlations between cognition and symptom level at either time point in BD participants.Conclusions: We found evidence of long‐term cognitive stability or improvement in BD participants from first treatment to 10‐year follow‐up. Though the BD group was impaired in all domains except mental speed and verbal fluency, the change in cognitive functioning was parallel to that of HCs. These findings are not consistent with the notion of neuroprogression in BD.


  • Open Access

    Early identification of treatment non-response in first-episode psychosis

    by Kristin Fjelnseth Wold, Akiah Ottesen, Bärthel Flaaten Camilla, Erik Johnsen, Trine Vik Lagerberg, Kristin Lie Romm, Carmen Simonsen, Torill Ueland, Line Widing, Gina Åsbø, et al.

    Background: Approximately one-third of patients with psychotic disorders does not respond to standard antipsychotic treatments. Consensus criteria for treatment resistance (TR) may aid the identification of non-response and subsequent tailoring of treatments. Since consensus criteria require stability of clinical status, they are challenging to apply in first-episode psychosis (FEP). This study aims to investigate (a) if an adaptation of consensus criteria can be used to identify FEP patients with early signs of TR (no early clinical recovery—no-ECR) after 1 year in treatment and (b) to what extent differences in antipsychotic treatments differentiate between outcome groups. Methods: Participants with FEP DSM-IV schizophrenia spectrum disorders were recruited during their first treatment. A total of 207 participated in the 1-year follow-up. Remission and recovery definitions were based on adaptations of the “Remission in Schizophrenia Working Group” criteria and TR on adaptations of the “Treatment Response and Resistance in Psychosis” (TRRIP) working group criteria. Results: 97 participants (47%) could be classified as no-ECR, 61 (30%) as ECR, and 49 (23%) as with partial ECR (P-ECR). Statistically significant baseline predictors of no-ECR matched previously identified predictors of long-term TR. Only 35 no-ECR participants had two adequate treatment trials and met the full TRRIP criteria. 21 no-ECR participants were using the same medication over the follow-up year despite the lack of significant effects. Conclusion: The difference in the percentage of FEP participants classified as no-ECR versus TR indicates that we may underestimate the prevalence of early TR when using consensus criteria.


  • Open Access

    Course of intellectual functioning in schizophrenia and bipolar disorder: a 10-year follow-up study

    by Camilla Bärthel Flaaten, Ingrid Melle, Erlend Gardsjord, Thomas Bjella, Magnus Johan Engen, Anja Vaskinn, Gina Åsbø, Kristin Fjelnseth Wold, Line Widing, Siv Hege Lyngstad, et al.

    Background: Intellectual functioning (IQ) is lower in schizophrenia patients compared to healthy controls, with bipolar patients intermediate between the two. Declines in IQ mark the onset of schizophrenia, while stability is generally found post-onset. There are to date few studies on long-term IQ development in bipolar disorder. This study presents 10-year follow-up data on IQ, including premorbid IQ estimates, to track the developmental course from pre-onset levels to long-term outcomes in both patient groups compared to healthy controls.Methods: We included 139 participants with schizophrenia, 76 with bipolar disorder and 125 healthy controls. Mixed model analyses were used to estimate developmental slopes for IQ scores from estimated premorbid level (NART IQ) through baseline (WASI IQ) measured within 12 months post-onset, to 10-year follow-up (WASI IQ), with pairwise group comparisons. The best fit was found using a model with a breakpoint at baseline assessment.Results: Only the schizophrenia group had significant declines from estimated premorbid to baseline IQ levels compared to controls. When comparing patient groups, schizophrenia patients had steeper declines than the bipolar group. Increases in IQ were found in all groups over the follow-up period.Conclusions: Trajectories of IQ from premorbid level to 10-year follow-up indicated declines from estimated premorbid level to illness onset in both patient groups, followed by increases during the follow-up period. Schizophrenia patients had a steeper decline than bipolar patients. During follow-up, increases indicate developmental improvement for both patient groups, but with a maintained lag compared to healthy controls due to lower premorbid levels.